From: A Value-Based Medicine cost-utility analysis of genetic testing for neovascular macular degeneration
Incremental % of patients undergoing early-treatment ranibizumab therapy due to genetic testing (# of patients) | Genetic testing/moni-toring medical costsa (000s) | Negative costsa (000s) | Total costs (direct medical + negative costs (000s) | Overall cost (direct medical + negative costs) per patient tested | QALY gain per patient screened | $/QALY |
---|---|---|---|---|---|---|
1 % (1618) | $2,082,402 | (−$66,180) | $2,016,222 | $2135 | 0.0010 | $2,094,915 |
2 % (3235) | $2,082,402 | (−$132,360) | $1,950,042 | $2065 | 0.0020 | $1,013,076 |
3 % (4853) | $2,082,402 | (−$198,540) | $1,883,862 | $1995 | 0.0031 | $652,463 |
4 % (6479) | $2,082,402 | (−$264,720) | $1,817,682 | $1925 | 0.0041 | $472,156 |
5 % (8088) | $2,082,402 | (−$330,900) | $1,751,502 | $1855 | 0.0051 | $363,973 |
10 % (16,175) | $2,082,402 | (−$661,800) | $1,420,602 | $1504 | 0.0102 | $147,605 |
10.1 % (16,504) | $2,082,402 | (−$675,036) | $1,407,366 | $1479 | 0.0103 | $144,000 |
13.2 % (21,358) | $2,082,402 | (−$878,341) | $1,204,061 | $1350 | 0.0135 | $100,000 |
15 % (24,263) | $2,082,402 | (−$992,700) | $1,089,702 | $1154 | 0.0153 | $75,482 |
20 % (32,351) | $2,082,402 | (−$1,323,600) | $758,801 | $803 | 0.0204 | $39,421 |
30 % (48,526) | $2,082,402 | (−$1,985,400) | $97,001 | $103 | 0.0306 | $3,360 |
34.6 % (56,048) | $2,082,402 | (−$2,293,138) | (−$210,736) | (−$223) | 0.0353 | (−$6,319) |
38.5 % (62,275) | $2,082,402 | (−$2,547,931) | (−$465,529) | (−$493) | 0.0392 | (−$12,564) |